Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 12, 2020

SELL
$7.96 - $12.42 $115,937 - $180,897
-14,565 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$5.4 - $13.37 $78,651 - $194,734
14,565 New
14,565 $140,000

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $418M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.